Smithkline Beckman Corporation

Smithkline Beecham Corporation

Other

Smithklein Beckman Corporation

Joseph A Finkelstein

Lawrence I Kruse

Thomas B Leonard

Joseph Weinstock

Richard McCulloch Keenan

Carl Kaiser

James Martin Samanen

James S Frazee

Judith Hempel

Angiotensin II receptor antagonists having the formula: ##STR1## which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.

Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists

Substituted imidazoles having angiotensin II receptor blocking activity

Angiotensin II receptor antagonists having the formula: ##STR1## which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.

Substituted 5-(alkyl)carboxamide imidazoles

Potent DBH inhibitors having the formula ##STR1## can be used to inhibit DBH activity in mammals.

Dopamine-.beta.-hydroxylase inhibitors

Potent dopamine-.beta.-hydroxylase inhibitors having the formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.

2-(N-Phenylakyl-N-formyl)amino-3-hydroxy-2-propenoic acids are intermediates for mercaptoimidazolecarboxylic acids which are dopamine-.beta.-hydroxylase inhibitors.

Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.

Growing community of inventors

Philadelphia, PA, United States of America

Joseph A Finkelstein